Drugs / BMS-986515
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07115745 | Sep 2025 → Mar 2029 expected | — | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986515 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07115745 ↗ |
| Modality | Cell therapy | “a healthy donor (HD) allogeneic CD19-targeted CART cell product” NCT07115745 ↗ |
| Target | CD19 | “allogeneic CD19-targeted Chimeric Antigen Receptor (CAR) T Cells” NCT07115745 ↗ |